Citius Pharmaceuticals Inc (CTXR)

[TheFinalCD]

Good Afternoon Traders,

I hope everyone liked our last pick which rocketed up 191% in 2 days to $0.07 after our alert at $0.024. For tomorrow we have something with even more potential!

We are Issuing an Immediate Alert on Citius Pharmaceuticals (CTXR)

CTXR is about as an exciting as a situation as I have ever seen in small caps; this is an undiscovered runner in the booming biotech field that has really big names behind it and is well funded moving forward. Everyone knows just how explosive these biotechs are!

BIOTECHS are about as explosive as it gets on the OTC and CTXR is no exception. Over the past 3 months alone CTXR has popped to $1 for over 100% move on 3 separate occasions. (Any time any news comes) Now that CTXR is back at $0.45 we are all over it in anticipation of the next run to $1.

CTXR started moving today! CTXR up 15% on a massive surge of volume!

Currently CTXR has 2 drugs in late stage development (one product in Phase 3 of FDA approval, and another in Phase 2) that could catapult this entire situation into a whole new stratosphere!

Citius Pharmaceuticals; CTXR is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.

For the full report on CTXR go here: http://www.microcapdaily.com/new-pick-is/?

Last year CTXR completed the acquisition of Leonard-Meron Biosciences, Inc. (“LMB”) LMB’s leading drug candidate, Mino-Lok™, is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (“CRBSIs”). Mino-Lok™ is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilm, eradicate the bacteria, provide anti-clotting properties to maintain patency, and salvage the indwelling central venous catheter (“CVC”).

Mino-Lok™ is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration (“FDA”) granted a Qualified Infectious Disease Product (“QIDP”) designation for Mino-Lok™. Receiving QIDP designation means that Mino-Lok™ is now eligible for Fast Track designation, Priority Review, and a five-year extension of market exclusivity. CEO Leonard Mazur said “Management is excited with the acquisition which has provided us immediate access to Mino-Lok™, a phase 3 ready program in a billion-dollar industry,”

CTXR hydrocortisone and lidocaine cream is targeting to become the first FDA –approved prescription product to treat hemorrhoids in the U.S.

In December CTXR provided details of its phase 3 trial for Mino-Lok™ Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI) in combination with appropriate systemic antibiotic(s), to salvage infected CVCs, to preserve central venous access, and to avoid the complications and morbidities associated with catheter removal and reinsertion.

Clinical trial startup activities are underway and Citius is recruiting and qualifying sites for the trial. The first patient is expected to be enrolled in early 2017.

CTXR Market Outlook:

The market potential of CTXR Hydrocortisone and Lidocaine Combination Cream is massive. Nearly 50% of adults will have experienced the pain, discomfort, itching, and bleeding associated with hemorrhoids at least once.
In the U.S. an estimated 10 million patients report symptoms of hemorrhoidal disease each year. According to IMS, over 25 million units of topical combination prescription products for hemorrhoids were sold in the United States. During the twelve-month period ended June 2012, comprising an estimated $80 million annual market.

The market potential for Mino-Lok™ is a billion dollar market. There is an important need to develop an alternative to the standard of care for catheter-related blood stream infections (CRBSIs). Of the approximately 7 million central venous catheters (CVCs) used annually, about 500,000 or 7% become infected leading to serious, life threatening infections.

The standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly and 15% to 20% of the procedures are associated with significant morbidity. There are currently no approved therapies to salvage infected CVCs.

CTXR has a highly compelling chart setup here! Currently base lined at its $0.50 support levels CTXR has made no less than 3 separate runs to the $1 level over the past 3 months. Every time any news comes on CTXR the stock has exploded over 100% in the last 3 months and we are looking for it to do it again!

Stay tuned for more updates!

Sincerely,
MicroCapDaily